Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysis

This publication has 51 references indexed in Scilit:

• The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Advanced NSCLC: A Meta-Analysis from 30 Randomized Controlled Clinical Trials
  PLOS ONE, 2013
• First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
  The Lancet Oncology, 2012
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2012
• The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
  BMJ, 2011
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
  The Lancet Oncology, 2011
• Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
  Annals of Oncology, 2011
• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
  Annals of Oncology, 2010
• Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment
  Clinical Cancer Research, 2008
• GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
  BMJ, 2008
• Measuring inconsistency in meta-analyses
  BMJ, 2003